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NK1 antagonists attenuate tau 
phosphorylation after blast 
and repeated concussive injury
Frances Corrigan1,2, Ibolja Cernak3, Kelly McAteer2, Sarah C. Hellewell3, 
Jeffrey V. Rosenfeld4,5, Renée J. Turner2 & Robert Vink1*
Exposure to repeated concussive traumatic brain injury (TBI) and to blast-induced TBI has been 
associated with the potential development of the neurodegenerative condition known as chronic 
traumatic encephalopathy (CTE). CTE is characterized by the accumulation of hyperphosphorylated 
tau protein, with the resultant tau tangles thought to initiate the cognitive and behavioral 
manifestations that appear as the condition progresses. However, the mechanisms linking concussive 
and blast TBI with tau hyperphosphorylation are unknown. Here we show that single moderate 
TBI, repeated concussive TBI and blast-induced mild TBI all result in hyperphosphorylation of tau 
via a substance P mediated mechanism. Post-injury administration of a substance P, NK1 receptor 
antagonist attenuated the injury-induced phosphorylation of tau by modulating the activity of several 
key kinases including Akt, ERK1/2 and JNK, and was associated with improvement in neurological 
outcome. We also demonstrate that inhibition of the TRPV1 mechanoreceptor, which is linked to 
substance P release, attenuated injury-associated tau hyperphosphorylation, but only when it 
was administered prior to injury. Our results demonstrate that TBI-mediated stimulation of brain 
mechanoreceptors is associated with substance P release and consequent tau hyperphosphorylation, 
with administration of an NK1 receptor antagonist attenuating tau phosphorylation and associated 
neurological deficits. NK1 antagonists may thus represent a pharmacological approach to attenuate 
the potential development of CTE following concussive and blast TBI.
The accumulation of perivascular, hyperphosphorylated tau at the base of sulci following repeated concussive 
TBI is a hallmark of CTE, with its initial anatomical distribution thought to be associated with local mechanical 
 damage1. Mechanosensation in the brain is mediated, in part, by members of the transient receptor potential 
(TRP) family of  channels2,3, namely TRPV1, TRPV4 and TRPA1, whose activation is linked to the release of 
the neuropeptide substance  P2,4. Substance P preferentially binds to the tachykinin NK1  receptor5 and has been 
shown to increase kinase  activity6–8, including that of JNK, Akt and ERK1/2. Notably these kinases, amongst 
others, have been associated with tau  phosphorylation9. We therefore hypothesized that TBI-induced mechanical 
activation of brain TRP receptors might lead to increased substance P release, subsequent activation of neuronal 
NK1 receptors and ultimately hyperphosphorylation of tau. We have used experimental models of both concus-
sive and blast injury to investigate this hypothesis.
Results
Following a single, moderate to severe diffuse TBI in  rats10, there was an injury dependent increase in substance 
P immunoreactivity in the cortex immediately below the TBI impact site at 24 h after injury (Fig. 1A). Such 
increases in cortical substance P immunoreactivity have been previously reported by us following moderate 
to severe TBI in both animal and humans, and have been identified as being predominantly perivascular in 
 origin4,10. In the present study, no significant increase in substance P occurred after a single mild (concussive) 
TBI (Fig. 1A), although there was a significant increase (p < 0.01) following repeated mild TBI in rats delivered 
as 3 injuries each at 5 days  apart11, such that cortical substance P immunoreactivity after the  3rd TBI was similar 
to that following a single moderate injury (Fig. 1B). Cortical ELISA assay confirmed the immunohistochemistry 
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findings following repeated mild TBI (Fig. 1C). These observations are consistent with previous reports demon-
strating that substance P release is amplified with increasing intensity of stimulus or with repeated  stimulation5, 
allowing substance P to diffuse away from the site of release and activate up to 5 times more neurons expressing 
NK1 receptors. This is particularly relevant to perivascular neurons where substance P would radiate away from 
the vasculature to activate surrounding neurons expressing NK1 receptors.
Cortical tau hyperphosphorylation was also evident 24 h after TBI. As with the substance P results, a single 
mild TBI did not result in significant cortical tau phosphorylation, while repeated mild TBI resulted in a sig-
nificant increase in tau phosphorylation (p < 0.001), with levels being similar to that observed following a single 
moderate injury (Fig. 2A). Notably, administration of an NK1 antagonist, EUC-00112, significantly attenuated 
(p < 0.001) the tau phosphorylation following both single moderate and repeated mild TBI. We have previously 
shown that induction of single and repeated mild TBI induces changes in kinase and phosphatase activity that 
may be associated with increased phosphorylation of tau  protein13. Moreover, others have shown that substance 
P increases kinase  activity6–8, including that of Akt, JNK and ERK1/2. Consistent with these observations, the 
NK1 antagonist EUC-001 reversed any changes in the phosphorylation of the Akt, JNK and ERK1/2 kinases at 
24 h after repeated mild TBI back to a sham (non-injured) state (Fig. 2B). Notably, total levels of the kinases did 
not change after TBI (data not shown). Of interest is the observation that a cell-impermeable NK1 antagonist, 
n-acetyl L-tryptophan (NAT), previously shown by us to be efficacious when administered early after moderate 
to severe  TBI14 had no effect on any injury-induced changes in kinase phosphorylation after repeated mild TBI 
as compared to the cell-permeable EUC-001 (Fig. 2B). This suggests that there is a need for the NK1 antagonist 
to cross the intact BBB and bind to the neuronal NK1 receptor to be effective in preventing tau phosphorylation. 
Figure 1.  Increases in substance P immunoreactivity following diffuse TBI in rats. Immunohistochemistry 
(A) typically demonstrates the presence of substance P positive cortical neurons (arrowed) immediately below 
the impact site at 24 h after the final injury. While no significant increase was observed after a single mild 
TBI (smTBI), clear increases in substance P immunoreactivity were observed with increased intensity of the 
injury and with repeated exposure to the mild injury (rmTBI). Cell counts (B) and ELISA assay (C) confirm 
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Confocal microscopy images obtained after TBI confirmed that NK1 receptors were indeed co-localized to 
neurons that demonstrated increased phosphorylated tau after TBI (Fig. 2C).
Tau hyperphosphorylation and development of CTE has also been reported in military personnel after expo-
sure to  blast1. Accordingly, we examined the efficacy of NK1 antagonists to attenuate tau phosphorylation in an 
experimental mouse model of mild blast-induced  TBI15. Following blast, a significant increase (p < 0.001) in brain 
tau phosphorylation (serine 396 epitope) was indeed observed at 28 days after injury (Fig. 3A), although in the 
present study, no significant increase was detected at 24 h (see supplementary information for full blots). There 
were no changes in total tau levels at either time point (data not shown). Administration of the NK1 antagonist 
at 30 min after blast injury significantly reduced (p < 0.001) levels of tau phosphorylation at 28 days back to sham 
levels (Fig. 3B). Administration of the NK1 antagonist also significantly improved (0.0001 < p < 0.05) neurologi-
cal outcome at both 24 h and 28 days on the rotarod, vertical and horizontal angleboard tests, and the 28-day 
outcome on the beamwalk test (Fig. 3C–F). Although the beamwalk performance at 24 h was improved by NK1 
Figure 2.  (A) Changes in cortical tau phosphorylation (AT180) at 24 h following single, mild TBI (smTBI), 
repeated mild TBI (rmTBI) or moderate TBI with and without NK1 antagonist (EUC-001) treatment. 
Mean ± SEM; n = 4–6/group; *** = p < 0.001 versus sham and smTBI; ††† = p < 0.001 versus no treatment. (B) 
Changes in phosphorylated kinase levels at 24 h following smTBI and rmTBI, with and without administration 
of the NK1 antagonist, EUC-001. NAT (n-acetyl-tryptophan) is a non, cell-permeable NK1 antagonist. Note 
that only the cell permeable NK1 antagonist EUC-001 returned post-injury phosphorylated kinase levels back 
to sham (non-injured) levels. Mean ± SEM; n = 5–6/group; * = p < 0.05, ** = p < 0.01 versus sham; ††† = p < 0.001 
versus vehicle and NAT treated animals. (C) Typical confocal microscopy images of cortical neurons expressing 
phosphorylated tau (AT180), NK1 receptors, and their colocalization in the merged image. Images were 
obtained at 24 h following a single moderate TBI.
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antagonist administration, this was marginally statistically insignificant in the current study (p = 0.06). Notably, 
the improvements in neurological outcome at 24 h occurred in the absence of any significant change in brain 
phosphorylated tau, suggesting that neurological outcome at this time point of 24 h was unrelated to the status 
of tau. In contrast, the improvement in neurological outcome at 28 days was clearly associated with decreased 
presence of phosphorylated tau.
Finally, we examined the role of mechanosensitive TRP channels in tau phosphorylation. While TRPV1, 
TRPV4 and TRPA1 all promote substance P release and respond to mechanical  stimuli3, the TRPV1 recep-
tor and its linkage to perivascular substance P release and kinase activation has been the most thoroughly 
 characterized16, including the identification of selective pharmacological antagonists. Moreover, the TRPV1 
receptor has been shown to activate in response to mechanical stimulation at the brain-fluid vascular  interface2,3, 
including to changes in blood  pressure17 which have been well described after TBI. Despite being just one of 
three TRP mechanoreceptors linked to neuronal substance P release, administration of the TRPV1 antagonist, 
capsazepine, 30 min prior to moderate single TBI significantly attenuated (p < 0.05) cortical tau phosphorylation 
at 24 h after the insult (Fig. 4A). In contrast, administering the TRPV1 antagonist at 30 min after the insult had 
no effect on tau phosphorylation, suggesting that post-insult inhibition of mechanosensitive TRP channels is of 
no benefit in halting the initiated injury cascade. Figure 4B summarizes the proposed injury cascade whereby 
Figure 3.  Changes in tau phosphorylation (serine 396, 50–60 kDa; arrow) and neurological outcome at 24 h 
and 28 days following blast TBI in mice, with and without administration of the NK1 antagonist EUC-001. 
Western blot images (A) and their quantitation (B) demonstrate a significant increase (p < 0.001) after injury 
versus shams, while treatment with the NK1 antagonist reduced the tau phosphorylation back to sham levels. 
Mean ± SEM; n = 6/group; *** = p < 0.001 versus no treatment. Improvements in neurological outcome were 
noted in rotarod performance (C), foot faults on the beam walk (D), and on the angleboard in the vertical (E) 
and horizontal position (F). Mean ± SEM; n = 6/group; * = p < 0.05, ** = p < 0.01, *** = p < 0.001 versus vehicle 
treated animals at the same time point.
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mechanical stimulation of TRP channels leads to tau phosphorylation via substance P release and activation of 
NK1 receptors. It has been previously shown that repeated or high intensity NK1 receptor activation promotes 
further substance P  release5.
Discussion
We have previously demonstrated that in diffuse, moderate TBI, treatment with an NK1 antagonist reduces acute 
neuronal cell death and improves associated neurological outcome; these actions are primarily mediated by the 
antagonist reducing the substance P induced increase in blood brain barrier  permeability10,14. Blood brain barrier 
permeability has also been reported to increase following a series of repeated concussive  TBIs18, which is consist-
ent with our current observation of profoundly increased substance P release after repeated mild TBI. However, 
we also demonstrate that the non, lipid-soluble NK1 antagonist, NAT, was ineffective in altering kinase profiles 
after repeated mild TBI as compared to the cell-permeable NK1 antagonist, EUC-001, suggesting that the barrier 
opening after each individual mild TBI was insufficient to permit central penetration of the non, lipid-soluble 
antagonist. Similar results have been described comparing the efficacy of lipid-soluble NK1 antagonists and non, 
lipid-soluble antagonists at later time points after moderate to severe  TBI14, time points when increased blood 
brain barrier permeability is still apparent, but to lesser size  molecules14. To avoid potential inefficacy through 
lack of central penetration, we now routinely utilize a lipid-soluble NK1  antagonist12 in all of our studies of TBI.
We have previously reported acute/sub-acute increases in brain phosphorylated tau following both a single 
moderate to severe injury and repeated mild  injury11,13 as well as following blast  injury15 and have replicated 
those results here. The acute/sub-acute increase in hyperphosphorylated tau contributes to secondary injury after 
TBI by promoting prolonged detachment of tau from microtubules and enhancing its aggregation. The normal 
function of tau is to promote stabilization of microtubules with repeated rounds of phosphorylation/ dephos-
phorylation to allow detachment and movement of cargo. When tau becomes hyperphosphorylated it remains 
detached, destabilizing microtubules and impairing axonal transport which is vital for vesicles and organelles 
to reach the  synapse19. This leads to deterioration of synapses, with eventual retrograde degeneration. Such 
ongoing tau-induced degeneration is consistent with reports of ongoing neuronal loss following single diffuse 
 TBI20,21, repeated mild  TBI22 and following blast  TBI15. Detached hyperphosphorylated tau is also more likely to 
aggregate, first as oligomers and then as paired helical filaments and ultimately neurofibrillary tangles. The early 
tau oligomers are thought to be particularly toxic, acting as templates for the misfolding of native tau, seeding 
the spread of toxic tau  species23, as well as directly disrupting synaptic  function24. Preventing acute alterations in 
tau phosphorylation may thus have long-term benefits after TBI. Indeed, complete ablation or partial reduction 
of tau prevented deficits in spatial memory on the Barnes Maze at one month after repeated  TBI25.
Given the detrimental effects of increased hyperphosphorylated tau following TBI, it is important to identify 
treatments that target this secondary injury factor. Here we show that preventing substance P signaling, either 
by blocking its NK1 receptor or by preventing its release using a TRPV1 mechanoreceptor antagonist, reduces 
levels of tau phosphorylation after TBI. This was associated with a restoration of kinase levels (Akt, ERK1/2, 
JNK) to normal (sham) levels. While repeated injury in the current study was associated with a decrease in 
the phosphorylated active forms of these kinases at the 24 h timepoint, kinase activation is  transient26 and the 
Figure 4.  (A) Effects of the TRPV1 antagonist, capsazepine (Cap), on 24 h tau phosphorylation (AT180) when 
administered 30 min prior to or 30 min following moderate TBI. Capsazepine administration significantly 
reduced tau phosphorylation only when administered prior to injury. Mean ± SEM; n = 6/group; * = p < 0.05 
versus nontreated animals. (B) Schematic summarizing mechanisms associated with tau phosphorylation 
following concussive and blast brain injury. Mechanical stimulation of transient receptor potential (TRP) 
receptors initiates substance P release, which binds to NK1 receptors. NK1 receptor stimulation activates 
kinases that then phosphorylate tau, leading to neurofibrillary tangles. Repeated or high intensity NK1 receptor 
activation can also promote further substance P  release5.
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acute increases immediately after TBI may have been missed at the 24 h time-point, resulting in the rebound 
decrease noted here after the phosphate group has been donated to the tau protein. Apart from direct modula-
tion of kinases, prevention of other secondary injury factors, including axonal injury and inflammation, via 
blockade of substance  P4 could also be important in reducing tau phosphorylation after TBI. The mechanical 
stress associated with TBI is known to alter the behavior of tau proteins, causing them to act more stiffly than 
usual, leading to mechanical breakdown of microtubules and release of  tau27. Axonal injury continues beyond 
this initial mechanical insult, with mechanoporation of the axonal membrane allowing influx of calcium and 
activation of calpain pathways that degrade the cytoskeleton including  microtubules28, permitting further release 
of tau and its subsequent phosphorylation. TBI also leads to upregulation of an acute inflammatory  response4, 
including pro-inflammatory cytokines like interleukin-1 and interleukin-6, which have been shown to promote 
phosphorylation of  tau29. Blockade of substance P via administration of an NK1 antagonist following moder-
ate to severe TBI has previously been shown to reduce axonal  injury14. Furthermore, substance P is known to 
amplify the classical inflammatory response, promoting microglia and astrocyte activation and the release of 
pro-inflammatory mediators including the cytokines interleukin-1 and interleukin-64,8. Thus, this inflammatory 
response may have been attenuated following administration of an NK1 antagonist or capsazepine, to further 
assist in reduction in tau phosphorylation post-injury.
In this study we have demonstrated that inhibition of substance P signaling prevents the acute increase in tau 
phosphorylation noted following both single moderate and repeated mild TBI, and the delayed increase seen 
after single mild blast injury. Alteration in tau phosphorylation is an important secondary injury factor after TBI 
with hyperphosphorylation of tau promoting its aggregation into oligomers, which are thought to act as seeds for 
further tau pathology and ongoing neuronal cell injury. While it is yet to be confirmed in larger, gyrencephalic 
animals that such tau hyperphosphorylation will be concentrated at the base of sulci where the greatest mechani-
cal loading occurs in response to  TBI30, our present results have nonetheless demonstrated that treatment with 
an NK1 antagonist acutely after single moderate to severe TBI, repeated mild TBI or mild blast injury may have 
long-term benefits, including attenuating the potential development of tau pathologies such as CTE.
Methods
All animal studies were carried out in compliance with the ARRIVE guidelines (http:// www. nc3rs. org. uk/ page. 
asp? id= 1357) as detailed below.
Ethical approval. Rat TBI studies were conducted in accordance with guidelines established by the 
National Health and Medical Research Committee of Australia and undertaken at the University of Adelaide 
following approval by the institutional Animal Ethics Committee. Mouse blast injury experiments were con-
ducted in accordance with Canadian Council on Animal Care (CCAC) guidelines and were undertaken in the 
Blast Research Facility of the Combat Casualty Care Division at the Defence Research Department of Canada 
(DRDC), Suffield following approval by both the University of Alberta and the DRDC Suffield Animal Ethics 
Committees.
Rat model of TBI. Male, Sprague–Dawley rats (350-400 g) were housed in a temperature-controlled envi-
ronment under a 12  h light/dark cycle with uninterrupted access to food and water before being randomly 
allocated to receive either sham procedures, a single moderate to severe TBI (TBI) or repeated mild TBI under 
anesthesia, as has been described in detail  previously11. Animals were anaesthetized via inhalation of 5% isoflu-
rane (Henry-Schein) using a normoxic mixture of air (70% nitrogen, 30% oxygen; BOC), at a rate of one liter 
per minute. Once absence of reflexes was apparent, animals were maintained on 2% inhalational isoflurane via 
a nose cone for the duration of the procedure. In brief, for the single moderate injury, a 400 g weight is dropped 
from 2 m onto a steel disc, whilst for repeated mild TBI, the weight is dropped from 1 m onto the steel disc on 
days 0, 5 and 10. Induction of three injuries with a 5-day time interval has been previously described as being 
optimal to produce cumulative long-term functional deficits with repeated mild  TBI11. Sham animals were anes-
thetized and underwent surgery without impact, with the sham group containing a mix of single surgery shams 
and repeated surgery shams (undertaken on days 0, 5 and 10). A 10 cm thick foam cushion decelerates the head 
after impact, thus producing the acceleration/deceleration injury. After injury, the skin overlying the injury site 
is sutured and the rats are returned to their home cage. Temperature is maintained throughout all procedures 
using a water-heated thermostatically controlled heating pad. Sham control animals undergo surgery, but do not 
receive an impact.
Mouse model of mild blast injury. Adult male C57Bl/6 mice (~ 10 weeks of age; Charles River Labo-
ratories, Montreal, Quebec, Canada) were housed in temperature-controlled rooms on a 12 h light/dark cycle 
with access to food and water ad libitum. After a 1-week acclimation period, animals were randomly allocated 
to receive either sham procedures or mild blast injury as previously described in detail  elsewhere31. Briefly, a 
custom-built Advanced Blast Simulator (ABS; 30.5 cm in diameter and 5.79 m in length) located at DRDC Suf-
field was used to produce a highly reproducible single pulse shock waves tailored to replicate those of explosive 
blast. Mice were anaesthetized with 3% isoflurane evaporated in 30% oxygen & 70% nitrous oxide in an induc-
tion chamber for two minutes, followed by an additional four minutes of administration via nose cone while the 
animal was secured to the blast holder. When deeply anesthetized (confirmed by the absence of tail, corneal and 
toe pinch reflexes), the blast holder was dispatched to the ABS and rotated so the mouse was in a bipedal position 
facing front-on to the blast wave, and the holder advanced into the shock tube a distance of 30 cm (2.4 m from 
the membrane) so as to expose the animal to a low intensity (10 psi) total blast pressure, approximating mTBI. 
This exposure was selected because it was the lowest exposure at which we were able to detect sensorimotor dys-
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function and pathology of the Purkinje cell layer of the cerebellum, which is a hallmark of clinical and preclinical 
blast  exposure31. The end-wave eliminator was then quickly secured and the blast sequence initiated. Sham mice 
were anaesthetized and secured to the blast holder as for the blast group, without transport to the shock tube. 
After blast exposure or sham procedure, mice were quickly removed from the holder by cutting the cable ties on 
one side and placed into a clear Perspex cage for acute neurological monitoring.
The blast-induced TBI model used in this work was developed based on our previously developed and 
standardized  models15,31, and the presence of the hallmarks of blast injury such as ecchymosis in the lungs, 
among others, have been verified by the Yelverton blast scoring system at 24-h time-point31,32. This system 
provides an excellent profile of whole-body damage by combining scores for the extent (E) of organ damage, 
the grade (G) of organ damage, the severity (ST) of pathology, and the severity depth (SD) to indicate the depth 
of disruption of the worst pathology observed. These scores are combined in the following formula to reach a 
final injury severity (IS) score: IS = (E + G + ST) x SD. Examination of whole-body pathology revealed evidence 
of lung injury consisting primarily of scattered petechial hemorrhages most prominent at the lung periphery. In 
some cases, small areas of hemorrhage involving less than 10% of the lungs were observed. Similar to the model 
used in Cernak et al.31 and Huber et al.  studies15, overall, the lung injury fell within the slight score based on the 
Yelverton blast injury scoring system. Pathological sequelae (manly petechiae and ecchymosis) in the liver and 
kidneys were also within the slight Yelverton score. As this model reproduced mild BINT, it was not surprising 
that these structural changes were not observed at the 28-day timepoint.
Drug treatments. After injury, randomly selected animals in each injury group were administered with 
either 1  mg/kg of the lipid soluble NK1 antagonist EUC-00112 (Eustralis Pharmaceuticals, Melbourne, Aus-
tralia), 2.5 mg/kg of the non-lipid soluble NK1 antagonist n-acetyl L-tryptophan (Sigma-Aldrich, Castle Hill, 
Australia), or equal volume saline vehicle. Drugs were administered as a single bolus i.v. in rats and i.p. in mice 
at 30 min after single injury, or 30 min after each injury induction following repeated mild TBI.
Group allocation. For examination of the effects of injury on SP expression, animals were allocated to 
sham, single mild, repeated mild and single moderate to severe injury with perfuse fixation at 24 h post-injury. 
A separate cohort of sham, smTBI and rmTBI animals were saline perfused and the brain frozen for cortical SP 
assessment. For analysis of the effects of NK1 antagonism on tau phosphorylation in the impact-acceleration 
model, animals were allocated to either sham, smTBI, rmTBI, modTBI, rmTBI + NK1 treatment and mod-
TBI + NK1 treatment and perfusion fixed at 24 h post-injury. A separate cohort were allocated to sham, smTBI, 
rmTBI, rmTBI + NAT or rmTBI + EUC-001, saline perfused and brains fresh frozen for analysis of kinase acti-
vation post-TBI. Mouse blast experiments followed a similar group allocation procedure, with mice randomly 
allocated to sham, single mild blast, or single mild blast + EUC-001. For all assessments, including neurological 
outcomes and pathology, assessors were routinely blinded to the group allocation.
Mouse neurological monitoring. At days 1 and 28 after injury, mice were assessed for neurological 
motor outcome using the inclined plane, rotarod and tapered beam walk tests (n = 6/group). In the angle board 
test, mice were assessed on their ability to grip onto an inclined board which was covered with a grooved rubber 
mat. The angle was increased in 5-degree increments, with ability to grip assessed facing vertically (up and down 
the incline) or horizontally (across the incline). The maximum angle at which a mouse was able to maintain its 
position for at least 5 s was taken as the score for that animal. In the rotarod test, animals were assessed on their 
ability to walk on a rotating assembly of rods, where the device speed increases by 3 revolutions per minute 
every 5 s. Each mouse was given three trials, with the average taken as the final score for revolutions per minute 
achieved. Animals were pretrained on the device for 1 week prior to induction of injury. For the tapered beam 
test, mice were required to traverse a one-metre-long beam placed on a 30° incline. At its widest, the beam is 
3.5 cm and decreases to 0.5 cm at the tip, with a lowered ledge on both sides to support foot faults. Mice with 
hind limb gait deficits are unable to keep their balance on the upper portion of the beam, requiring extra support 
from the ledged portion of the beam. Mice were given one training session and one trial per testing period, with 
the number of hind limb foot slips to the lower portion recorded.
Biochemical analysis. Rats were terminally with isoflurane prior to transcardial perfusion with saline. The 
brains were removed, the cortex under the impact site dissected and snap frozen. Protein was then extracted, 
with protein concentration estimated with a Pierce BCA Protein Assay (Thermo Scientific, Waltham, MA, USA). 
Levels of SP within homogenates were measured via a SP Parameter Assay Kit (KGE007, R&D Systems, Min-
neapolis MN, USA) as per the manufacturer’s protocol, with all samples measured in triplicate (n = 5–6/group). 
Analysis of kinases (Akt, ERK1/2 and JNK) was performed using custom made Bio-Plex Pro Cell Signaling 
Assay kits (Bio-Rad, Hercules, CA, USA) as per the manufacturer’s protocol (typically n = 5/group). The plate 
was then loaded into a Bio-Plex MAGPIX reader (Bio-Rad) and the output read by Bio-Plex Manager Software 
(Bio-Rad). Readings were then collated and analyzed statistically.
Western blotting. Brains of blast-exposed and sham control mice were assessed for tau and its phospho-
rylation by Western blot as previously described in detail  elsewhere15. Briefly, protein extracts were prepared 
from dissected brains (n = 6/group) consisting predominantly of cortex but also including underlying subcorti-
cal thalamic regions. TGX gels (4–20%; Bio-Rad) were then loaded with 20 μg/lane and probed after overnight 
incubation (4 °C) with antibodies for phosphorylated tau AT8 (Thermoscientific) and serine 396 (Life Technolo-
gies, Grand Island NY, USA). Probes for total tau (tau5) and pyruvate kinase (Rockland, Gilbertsville, PA) were 
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conducted after stripping. Target bands were densitometrically analyzed with ImageQuant TL (GE, Piscataway, 
NJ), with tau epitope levels standardized to total tau level and expressed relative to sham.
Immunohistochemistry. Rats (typically 6/group) were terminally anaesthetised and transcardially per-
fused with 10% formalin before their brains were removed and stored in 10% formalin until use. Five μm sec-
tions were collected at 250 μm intervals, representing the region from Bregma − 2.5 to 3 mm. Sections were 
then stained for levels of tau phosphorylation (AT180, 1:1000, MN1040, Thermo Fisher) or SP (1:1000, ab10353, 
Abcam, Cambridge MA, USA). Following dewaxing, endogenous peroxidases were blocked with methanol/
hydrogen peroxide (0.5%), followed by antigen retrieval in citrate buffer. Sections were then incubated with 
30% normal horse serum for 1 h, prior to incubation overnight at room temperature with the specific primary 
antibody. The next day, the appropriate biotinylated secondary antibody (1:250, Vector Laboratories, Burlingame 
CA, USA) was applied for 30 min, followed by streptavidin horseradish peroxidase for 60 min, with the bound 
antibody detected with 3,3-diaminobenzidine tetrahydrochloride (Sigma-Aldrich). Sections were counter-
stained with hematoxylin. Slides were digitally scanned using a Nanozoomer (Hamamatsu Nanozoomer 2.0RS, 
Japan) viewed with the associated NDP view software, with images exported for analysis with Image  J10. For 
quantitation, a box (0.4  mm2) was placed in four locations within the cortex of each section and all cell bodies 
greater than 7.5 μm in size, to exclude most non-neuronal cells were counted as either AT180 + ve or –ve. Counts 
were performed twice and standard deviation between counts was typically < 10%. For double labelling images 
were incubated NK1 antibody (ab466) and AT180, followed by fluorescent-conjugated secondary antibody 
(1:250 dilution, Sigma-Aldrich). The slides were counterstained with DAPI for total nuclei counting and imaged 
with an Olympus BX61 microscope with motorised stage using the imaging software, analySIS Lifescience.
Statistical methods. Statistical analysis of all data was performed by using GraphPad Prism version 6.0 
for Macintosh (GraphPad, La Jolla CA, USA). Normality assumptions were assessed using the D’Agostino and 
Pearson omnibus normality test. All data was assessed by two-way ANOVA and where overall significance was 
detected, post hoc Tukey or Dunnett’s t-tests were employed to determine significance at individual treatment 
levels between timepoints. All data are shown as mean ± SEM and a p value of less than 0.05 was considered 
statistically significant (Suppl. Fig. S1).
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